BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled

Systemic lupus erythematosus (SLE) is a complex immune disorder in which loss of tolerance to nucleic acid antigens and other cross-reactive antigens is associated with the development of pathogenic autoantibodies that damage target organs including the skin, joints, brain, and kidney. B cells are e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Immunological reviews 2008-06, Vol.223 (1), p.156-174
Hauptverfasser:	Ramanujam, Meera, Davidson, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Blocking - administration & dosage Antibodies, Blocking - adverse effects autoantibodies B cells B-Cell Activating Factor - antagonists & inhibitors B-Cell Activating Factor - genetics B-Cell Activating Factor - immunology B-Lymphocytes - drug effects B-Lymphocytes - immunology BAFF Cell Survival - drug effects Cell Survival - immunology Gene Expression Regulation - drug effects Gene Expression Regulation - immunology Humans Immunoglobulin Class Switching - drug effects Immunoglobulin Class Switching - genetics Immunotherapy Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - therapy Mice Myeloablative Agonists - administration & dosage Myeloablative Agonists - adverse effects Self Tolerance - drug effects SLE therapeutics therapy TLRs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!